| Prev Close | 73.50 |
| Day Low/High | 72.71 / 73.49 |
| 52 Wk Low/High | 60.89 / 85.97 |
| Avg Volume | 24.66M |
Gilead Sciences Inc. (GILD)
73.34
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 1.25B |
| Market Cap | 92.17B |
| EPS | 4.20 |
| P/E Ratio | 18.85 |
| Div & Yield | 2.72 (3.48%) |
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Gilead Sciences Is Sporting a Bearish Set of Charts for Investors
Gilead has been trying to turn things around but few see that turn coming anytime soon.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Be Ready to Ride the Dividend on Gilead Sciences
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Gilead Has Strengthened So Go Long and Add to Longs
Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Biotech Stocks Rally on Biogen's Landmark Test
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Gilead Sciences Is Displaying a Bullish Long-Term Pattern
This biotech's weekly chart is very encouraging.
Jim Cramer: Confounding Days
The buyers of stocks on days like Tuesday make very little sense.
Jim Cramer: A GLUM Index For Gloomy Markets
Taking the measure of what's keeping the markets in the dumps.
Galmed Soars on Encouraging Trial Results
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...
Jim Cramer: Move Over FANG, Long Live INJFANG
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
Surveying the M&A Landscape in Biotech
Who might be in play in the quarters ahead?
Are Apple's Best Days in the Past?: Market Recon
I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
Bret Jensen's Biotech Mailbag
We'll answer two of the common questions we have received so far in March.
A Regular Winning Trade Becomes Roadkill in Market Meltdown
Maybe inverse and/or leveraged positions are perverse in nature.
These 2 Biotech Stocks Still Have Upside
The biotech sector has seen a big rally, but there are still opportunities.
Cramer: Step Away and Get Your Clients Better Prices
You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Circle These Biotech Acquisition Candidates
Outside of oncology, the rare disease area is a good target for M&A in 2018.
